1-acetyl-2-methylindoline-5-sulfonyl chloride | 841275-78-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-acetyl-2-methylindoline-5-sulfonyl chloride
• 英文别名: 5-Chlorsulfonyl-1-acetyl-2-methylindolin；1-acetyl-2-methyl-2,3-dihydroindole-5-sulfonyl chloride
• CAS: 841275-78-3
• 化学式: C₁₁H₁₂ClNO₃S
• mdl: MFCD07841689
• 分子量: 273.74
• InChiKey: VMIKNPLJAZXOOM-UHFFFAOYSA-N

物化性质

• 熔点：
  143-145

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  62.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-acetyl-2-methylindoline-5-sulfonyl chloride 在 吡啶 、 五氯化磷 、 碳酸氢钠 、 sodium sulfite 作用下， 以 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 1.5h， 生成 3-(1-Acetyl-2-methyl-2,3-dihydro-1H-indole-5-sulfonyl)-N-(3-trifluoromethyl-phenyl)-propionamide
  参考文献：
  名称：

  新型 3-(杂环基磺酰基)丙酸及其酰胺衍生物的简便合成

  摘要：

  从相应的杂环化合物开始，以高收率和高纯度制备了大量新型 3-（杂环基磺酰基）丙酸及其酰胺衍生物。首先，氯磺酸盐是通过初始杂环与各种磺化剂和氯化剂反应生成的，然后将它们转化为亚磺酸钠。用丙烯酸处理亚磺酸盐可以顺利得到一系列磺酰丙酸盐，它们可用作制备大量相应甲酰胺衍生物的方便试剂。

  DOI：

  10.1055/s-2004-834888
• 作为产物：
  描述：

  2-甲基吲哚啉 在 吡啶 、 氯磺酸 、 五氯化磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-acetyl-2-methylindoline-5-sulfonyl chloride
  参考文献：
  名称：

  Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation

  摘要：

  NOD1 (nucleotide-binding oligomerization domain 1) protein is a member of the NLR (NACHT and leucine rich repeat domain containing proteins) protein family, which plays a key role in innate immunity as a sensor of specific microbial components derived from bacterial peptidoglycans and induction of inflammatory responses. Mutations in NOD proteins have been associated with various inflammatory diseases that affect NF-kappa B (nuclear factor kappa B) activity, a major signaling pathway involved in apoptosis, inflammation, and immune response. A luciferase-based reporter gene assay was utilized in a high-throughput screening program conducted under the NIH-sponsored Molecular Libraries Probe Production Center Network program to identify the active scaffolds. Herein, we report the chemical synthesis, structure-activity relationship studies, downstream counterscreens, secondary assay data, and pharmacological profiling of the 2-aminobenzimidazole lead (compound 1c, ML130) as a potent and selective inhibitor of NOD 1-induced NF-kappa B activation.

  DOI：

  10.1021/ml200158b

文献信息

• [EN] COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR LE TRAITEMENT DE FIBROSE KYSTIQUE
  申请人：FLATLEY DISCOVERY LAB

  公开号：WO2014160478A1

  公开（公告）日：2014-10-02

  The invention relates to a compound of Formula I and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof.

  本发明涉及一种式I的化合物以及治疗囊性纤维化的方法，包括向需要的患者施用式I或IA化合物的治疗有效量的步骤。
• [EN] SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS DE SULFONAMIDE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：TROBIO THERAPEUTICS PTY LTD

  公开号：WO2021072487A1

  公开（公告）日：2021-04-22

  The present disclosure relates generally to a class of sulfonamide-based compounds, compositions containing the same and the therapeutic use of the compounds in the treatment of cancer.

  本公开涉及一类基于磺胺酰胺的化合物，包含这些化合物的组合物以及这些化合物在治疗癌症中的治疗用途。
• Discovery of a Novel Noniminosugar Acid α Glucosidase Chaperone Series
  作者：Jingbo Xiao、Wendy Westbroek、Omid Motabar、Wendy A. Lea、Xin Hu、Arash Velayati、Wei Zheng、Noel Southall、Ann Marie Gustafson、Ehud Goldin、Ellen Sidransky、Ke Liu、Anton Simeonov、Rafael J. Tamargo、Antonia Ribes、Leslie Matalonga、Marc Ferrer、Juan J. Marugan

  DOI：10.1021/jm3005543

  日期：2012.9.13

  Pompe disease is an autosomal recessive lysosomal storage disorder (LSD) caused by deficiency of the lysosomal enzyme acid a-glucosidase (GAA). Many disease-causing mutated GAA retain enzymatic activity but are not translocated from endoplasmic reticulum (ER) to lysosomes. Enzyme replacement therapy (ERT) is the only treatment for Pompe disease but remains expensive, inconvenient, and does not reverse all disease manifestations. It was postulated that small molecules which aid in protein folding and translocation to lysosomes could provide an alternate to ERT. Previously, several iminosugars have been proposed as small-molecule chaperones for specific LSDs. Here we identified a novel series of noniminosugar chaperones for GAA. These moderate GAA inhibitors are shown to bind and thermostabilize GAA and increase GAA translocation to lysosomes in both wild-type and Pompe fibroblasts. AMDE and physical properties studies indicate that this series is a promising lead for further pharmacokinetic evaluation and testing in Pompe disease models.
• SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER
  申请人：Trobio Therapeutics Pty Ltd

  公开号：EP4028395A1

  公开（公告）日：2022-07-20
• COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
  申请人：Flatley Discovery Lab, LLC

  公开号：US20170313659A1

  公开（公告）日：2017-11-02

  The invention relates to a compound of Formula I and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof: